Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inc ...

OPKO Health, Inc. (NASDAQ:OPK) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Yvonne Briggs - Investor Relations Phillip Frost - Chairman & Chief Executive Officer Steve Rubin - Executive Vice President Jon Cohen - Managing Director, Executive Chairman of BioReference Laboratories Adam Logal - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Operator Good day, ladies and gentlemen. And welcome to the OPKO Health Inc. Fourth Quarter 2021 Finan ...

OPKO Health Inc. (NASDAQ:OPK) Q3 2021 Financial Results Conference Call October 28, 2021 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Phillip Frost – Chairman and Chief Executive Officer Steve Rubin – Executive Vice President Jon Cohen – Senior Vice President, BioReference Laboratories Adam Logal – Chief Financial Officer Conference Call Participants Kevin Strang – Jefferies Edward Tenthoff – Piper Sandler Jeffrey Cohen – Ladenburg Yale Jen – Laidlaw & Company Operator Good day, la ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdicti ...

OPKO Health, Inc. (NASDAQ:OPK) Q2 2021 Earnings Conference Call July 29, 2021 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & CEO Steven Rubin - EVP, Administration & Director Jon Cohen - SVP & Director Adam Logal - SVP & CFO Conference Call Participants Maurice Raycroft - Jefferies Edward Tenthoff - Piper Sandler & Co. I Eh Jen - Laidlaw & Company Operator Good afternoon, ladies and gentlemen and welcome to the OPKO Health Second Quarter 2021 Financial Resu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of ...

OPKO Health, Inc. Conference Call Summary Company Overview - OPKO Health, Inc. is involved in various projects including diagnostics, licensing agreements, and drug development, particularly in response to pandemic needs [4][6] Key Business Segments Pharmaceutical Division - **Rayaldee**: The only commercial product, sales growth impacted by the pandemic, with optimism for recovery as practices reopen [6] - **Label Expansions**: Plans for trials related to haemodialysis and COVID-19, with enrollment challenges due to vaccination progress [6][7] - **Growth Hormone**: PDUFA date in October for the U.S., with potential significant milestones upon approval and profit-sharing with Pfizer [7][8] Diagnostics Division - **BioReference Laboratories**: A full-service lab with expertise in women's health, oncology, and genetics, significantly increased COVID-19 testing capacity [9][10] - **COVID-19 Testing**: Conducted nearly 16 million tests, with a shift from testing for disease to surveillance testing [21][22] - **Digital Solutions**: Introduction of Scarlet, a home digital solution for lab tests, enhancing convenience and service delivery [17][18] GeneDx - Focused on rare pediatric diseases, showing strong performance post-pandemic with increased demand for genetic testing [11][14] - Partnership with Mednax to enhance NICU testing capabilities, aiming for early diagnosis of genetic abnormalities [14][47] Financial Performance - As of March 31, OPKO had approximately $90 million in cash and $165 million available on credit lines, with four consecutive quarters of operating profit due to COVID testing [12][26] - Guidance for Q2 includes 3 to 4 million COVID tests, projecting revenue between $385 million and $450 million [26] Market Dynamics - The base business is currently about 7% off pre-COVID levels, with expectations for gradual recovery as more people return to offices [17] - Continued interest in large-scale testing for schools and sports franchises, with ongoing discussions for contract renewals [21][24] Future Catalysts - Anticipated launch of Scarlet in more markets, with significant announcements expected in the coming weeks [46] - Potential for GeneDx to expand testing capabilities for a larger population of infants with undiagnosed genetic conditions [47][48] Regulatory and Competitive Landscape - Pfizer controls pricing for the growth hormone, with expectations for a rapid market switch to long-acting formulations [33][40] - Ongoing interactions with regulators as part of the approval process for new products [41] Conclusion - OPKO Health is positioned for growth with a strong focus on digital solutions, expanding diagnostic capabilities, and potential milestones in pharmaceutical products, particularly in the growth hormone market and pediatric genetic testing [48][49]

OPKO Health, Inc. (NASDAQ:OPK) Q1 2021 Earnings Conference Call April 28, 2021 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & CEO Steven Rubin - EVP, Administration & Director Jon Cohen - SVP & Director Adam Logal - SVP & CFO Antonio Cruz - Chairman & CEO, Transition Therapeutics Inc. Conference Call Participants Maurice Raycroft - Jefferies Dana Flanders - Guggenheim Securities Edward Tenthoff - Piper Sandler & Co. I-Eh Jen - Laidlaw & Company Operator Goo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction o ...

OPKO Health, Inc. (NASDAQ:OPK) Q4 2020 Earnings Conference Call February 18, 2021 4:30 PM ET Company Participants Yvonne Briggs - LHA IR Phillip Frost - Chairman and CEO Steven Rubin - EVP Jon Cohen - SVP, Executive Chairman, BioReference Laboratories Adam Logal - CFO Charlie Bishop - CEO, OPKO Renal Conference Call Participants Maury Raycroft - Jefferies Devin Geiman - Guggenheim Partners Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw and Company Yi Chen - HCW Mike Petusky - Barrington Research Operato ...